Valuation : Evofem Biosciences, Inc.

Market Cap 1.02M 879K 833K 755K 1.42M 97.49M 1.42M 9.89M 3.8M 49.6M 3.83M 3.75M 157M P/E 2024
-0.08x
P/E 2025 26.7x
Enterprise Value 55.44M 47.76M 45.23M 40.99M 76.91M 5.3B 77.3M 537M 207M 2.69B 208M 204M 8.51B EV / Sales 2024
2.43x
EV / Sales 2025 2.76x
Free-Float
100%
Yield 2024 *
-
Yield 2025 -
1 day+7.59%
1 week+10.39%
Current month+3.03%
1 month+18.06%
3 months+7.59%
6 months-7.61%
Current year-10.53%
1 week 0.01
Extreme 0.007
0.01
1 month 0.01
Extreme 0.0067
0.01
Current year 0
Extreme 0.0008
0.01
1 year 0
Extreme 0.0008
0.02
3 years 0
Extreme 0.0008
0.23
5 years 0
Extreme 0.0008
1,581
10 years 0
Extreme 0.0008
23,549.99
Manager TitleAgeSince
Chief Executive Officer 57 01/01/2018
Director of Finance/CFO 49 13/04/2023
Chief Operating Officer - -
Director TitleAgeSince
Chairman 57 -
Director/Board Member 67 01/01/2018
Director/Board Member 58 01/01/2018
Date Insider Type Main position Quantity % Market Cap. Importance
12/1/24 Sell

Chief Financial Officer

104 0.0010%
21/12/23 Sell

Director

10 0.0001%
13/4/23 Other

Chief Financial Officer

13,000 0.0107%
Change 5-day change 1-year change 3-year change Capi.($)
+7.59%+10.39%-45.16%-94.97% 1.02M
-0.65%-2.93%+47.70%+86.17% 994B
-0.29%-3.51%+49.15%+62.35% 640B
+0.83%+0.26%+17.76%+72.25% 454B
-0.38%-3.59%+30.13%+35.17% 337B
-0.09%-13.54%+13.34%+24.95% 261B
-0.43%-2.48%-0.73%+9.58% 246B
-1.34%-13.70%+36.53%+44.96% 204B
-3.44%-7.51%-20.63%-59.44% 190B
-0.75%-4.82%+25.46%+87.14% 178B
Average +0.11%-4.80%+15.36%+26.82% 350.48B
Weighted average by Cap. -0.51%-4.11%+30.96%+54.95%

Financials

2024 2025
Net sales 19.36M 16.68M 15.8M 14.32M 26.86M 1.85B 27M 188M 72.15M 941M 72.72M 71.12M 2.97B 20.18M 17.39M 16.47M 14.92M 28M 1.93B 28.14M 196M 75.2M 981M 75.8M 74.14M 3.1B
Net income -8.86M -7.63M -7.23M -6.55M -12.29M -846M -12.35M -85.85M -33.01M -431M -33.27M -32.54M -1.36B 391K 337K 319K 289K 542K 37.35M 545K 3.79M 1.46M 19M 1.47M 1.44M 60.05M
Net Debt 45.84M 39.5M 37.4M 33.9M 63.59M 4.38B 63.91M 444M 171M 2.23B 172M 168M 7.04B 54.42M 46.89M 44.39M 40.24M 75.49M 5.2B 75.87M 527M 203M 2.64B 204M 200M 8.36B
Logo Evofem Biosciences, Inc.
Evofem Biosciences, Inc. is a commercial-stage biopharmaceutical company. The Company is commercializing its products to address unmet needs in women’s sexual and reproductive health. The Company’s first approved product, PHEXXI (lactic acid, citric acid, and potassium bitartrate), is a hormone-free, on-demand prescription contraceptive vaginal gel. It comes in a box of over 12 pre-filled applicators and is applied 0-60 minutes before each act of intercourse. PHEXXI is a gel that works to prevent pregnancy without the use of hormones. PHEXXI prevents pregnancy by reducing sperm motility, inhibiting sperm from reaching the ovum to form a zygote. Using the PHEXXI telehealth platform, women can directly meet with a health care provider to determine their eligibility for a PHEXXI prescription. The Company also commercialized SOLOSEC (secnidazole) 2g oral granules, an antibiotic for the treatment of two sexual health diseases such as bacterial vaginosis and trichomoniasis.
Employees
29
Date Price Change Volume
11/09/26 US$0.007700 -0.65% 84,827
10/09/26 US$0.007750 +6.16% 12,529
09/09/26 US$0.007300 +2.82% 221,679
08/09/26 US$0.007100 -7.79% 643,430
04/09/26 US$0.007700 +2.67% 52,384

Annual profits - Rate of surprise

  1. Stock Market
  2. Stocks
  3. EVFM Stock
40% Discount: Identify Tomorrow's Best Investments With The Best Subscriber-Only Tools!
d
:
:
SEIZE THE OFFER!